BioCryst Pharmaceuticals, Inc.
BCRX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $1,554 | $1,151 | $2,134 | $2,481 |
| - Cash | $105 | $111 | $305 | $504 |
| + Debt | $841 | $849 | $741 | $593 |
| Enterprise Value | $2,291 | $1,889 | $2,571 | $2,570 |
| Revenue | $451 | $331 | $271 | $157 |
| % Growth | 36% | 22.4% | 72.3% | – |
| Gross Profit | $438 | $327 | $264 | $150 |
| % Margin | 97.2% | 98.6% | 97.6% | 95.4% |
| EBITDA | $13 | -$116 | -$144 | -$122 |
| % Margin | 2.8% | -35.1% | -53.1% | -77.5% |
| Net Income | -$89 | -$227 | -$247 | -$184 |
| % Margin | -19.7% | -68.4% | -91.2% | -117.1% |
| EPS Diluted | -0.43 | -1.18 | -1.33 | -1.03 |
| % Growth | 63.6% | 11.3% | -29.1% | – |
| Operating Cash Flow | -$52 | -$95 | -$162 | -$142 |
| Capital Expenditures | -$1 | -$2 | -$1 | -$2 |
| Free Cash Flow | -$53 | -$97 | -$163 | -$145 |